Reply to Denning [4]

Clinical Infectious Diseases

Volumn 45, Issue 8, 2007, Pages 1108-1110

  Cornely, Oliver A ^a   Maertens, Johan ^c   Ullmann, Andrew J ^b   Heussel, Claus Peter ^c   Herbrecht, Raoul ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b University Hospital Gasthuisberg   (Netherlands)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; GALACTOMANNAN; VORICONAZOLE;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LETTER; LUNG LAVAGE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL;

EID: 35348850070     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521943     Document Type: Letter

References (11)

1. Denning DW. Comparison of 2 studies of treatment of invasive aspergillosis. Clin Infect Dis 2007; 45:1106-8 (in this issue).
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin Bfor primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
3. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97.
4. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
5. Cornely OA, Maertens J, Bresnik M, Herbrecht R, Ebrahimi R. Factors associated with mortality in a trial of liposomal amphotericin B as initial therapy for invasive filamentous fungal infections. In: Program and abstracts of 2nd Advances Against Aspergillosis. Athens, Greece, 2006:219.
6. de Pauw BE, Patterson TF. Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005; 41(Suppl 6):S377-80.
7. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
8. Verweij PE, van Die L, Donnelly JP. Halo sign and improved outcome. Clin Infect Dis 2007; 44:1666-7; author reply 7-8.
9. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44:373-9.
10. Anaissie EJ. Trial design for mold-active agents: time to break the mold - aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44:1298-306.
11. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomographyscans in patients with neutropenia. J Clin Oncol 2001; 19:253-9.